These Analysts Think Cellectis S.A.'s (EPA:ALCLS) Sales Are Under Threat

The analysts covering Cellectis S.A. (EPA:ALCLS) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative.

Following the latest downgrade, the current consensus, from the seven analysts covering Cellectis, is for revenues of US$72m in 2021, which would reflect a considerable 13% reduction in Cellectis' sales over the past 12 months. Prior to the latest estimates, the analysts were forecasting revenues of US$79m in 2021. It looks like the analysts have become a bit less bullish on Cellectis, given the slight decrease in revenue estimates after the latest consensus updates.

View our latest analysis for Cellectis

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Cellectis' past performance and to peers in the same industry. One more thing stood out to us about these estimates, and it's the idea that Cellectis' decline is expected to accelerate, with revenues forecast to fall at an annualised rate of 13% to the end of 2021. This tops off a historical decline of 4.3% a year over the past five years. Compare this against analyst estimates for companies in the broader industry, which suggest that revenues (in aggregate) are expected to grow 32% annually. So while a broad number of companies are forecast to grow, unfortunately Cellectis is expected to see its sales affected worse than other companies in the industry.

The Bottom Line

The most important thing to take away is that analysts cut their revenue estimates for this year. They're also anticipating slower revenue growth than the wider market. Overall, given the drastic downgrade to this year's forecasts, we'd be feeling a little more wary of Cellectis going forwards.

But wait - there's more! We have estimates for Cellectis from its seven analysts out until 2025, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

If you decide to trade Cellectis, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account. Promoted

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
^*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.